AGITATION

This study tests whether nabilone, a synthetic cannabinoid, can safely reduce agitation in people with Alzheimer's disease. Agitation is common and distressing, with few effective treatments. About 112 participants will receive either nabilone or a placebo for 8 weeks, and resear…

This study tests an oral medication (BMS-986368) to reduce agitation in people with Alzheimer's disease. About 120 participants will receive either the drug or a placebo. The main goal is to see if the drug can decrease agitated behaviors like restlessness or aggression, as measu…

This study tests the long-term safety of an experimental drug combination (KarXT) for treating agitation in people with Alzheimer's disease. About 600 participants who completed earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug r…

This study tests a medicated skin patch (dexmedetomidine) to see if it can reduce agitation in people with Alzheimer's dementia. About 150 participants living in care facilities will receive either the patch or a placebo. The main goal is to measure changes in agitated behavior o…

This study tests whether the drug masupirdine can safely reduce agitation in people with Alzheimer's dementia. About 375 participants will receive either the drug or a placebo. The main goal is to see if agitation symptoms like aggression and restlessness improve.

This study tests whether a robotic seal called PARO can help reduce agitation, anxiety, and pain in adults after visceral surgery. 300 participants will either use PARO or receive standard care. The robot responds to touch and voice to calm patients. The goal is to see if this fr…

This study tests a new brain activity monitor in 100 ICU patients who are on breathing machines and sedatives. The monitor uses a simple forehead patch to track brain signals and see if it matches standard checks for sedation and delirium. The goal is to find a better way to moni…